116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa
| Autor: | González-Santiago, S., López-Miranda, E., Escrivá-De-Romaní, S., Jiménez-Rodríguez, B., Antolín-Novoa, S., González-Cortijo, L., Fernández-Morales, L.A., Galve-Calvo, E., Martorell, A. Perello, Arroyo-Rivera, I., García-Bernáldez, C., Lagunar-Ruiz, J., Gavilá-Gregori, J. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|